Logo image of CABA

CABALETTA BIO INC (CABA) Stock Fundamental Analysis

NASDAQ:CABA - US12674W1099 - Common Stock

1.675 USD
-0.02 (-1.47%)
Last: 9/8/2025, 12:21:00 PM
Fundamental Rating

1

Taking everything into account, CABA scores 1 out of 10 in our fundamental rating. CABA was compared to 541 industry peers in the Biotechnology industry. Both the profitability and financial health of CABA have multiple concerns. CABA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CABA had negative earnings in the past year.
CABA had a negative operating cash flow in the past year.
CABA had negative earnings in each of the past 5 years.
In the past 5 years CABA always reported negative operating cash flow.
CABA Yearly Net Income VS EBIT VS OCF VS FCFCABA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

CABA has a Return On Assets of -64.27%. This is comparable to the rest of the industry: CABA outperforms 41.04% of its industry peers.
CABA has a Return On Equity of -80.84%. This is comparable to the rest of the industry: CABA outperforms 52.31% of its industry peers.
Industry RankSector Rank
ROA -64.27%
ROE -80.84%
ROIC N/A
ROA(3y)-44.86%
ROA(5y)-40.06%
ROE(3y)-51.8%
ROE(5y)-45.02%
ROIC(3y)N/A
ROIC(5y)N/A
CABA Yearly ROA, ROE, ROICCABA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100

1.3 Margins

CABA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CABA Yearly Profit, Operating, Gross MarginsCABA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

3

2. Health

2.1 Basic Checks

The number of shares outstanding for CABA has been increased compared to 1 year ago.
The number of shares outstanding for CABA has been increased compared to 5 years ago.
Compared to 1 year ago, CABA has a worse debt to assets ratio.
CABA Yearly Shares OutstandingCABA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CABA Yearly Total Debt VS Total AssetsCABA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -2.04, we must say that CABA is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of CABA (-2.04) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.02 indicates that CABA is not too dependend on debt financing.
CABA's Debt to Equity ratio of 0.02 is in line compared to the rest of the industry. CABA outperforms 42.14% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z -2.04
ROIC/WACCN/A
WACCN/A
CABA Yearly LT Debt VS Equity VS FCFCABA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

CABA has a Current Ratio of 4.78. This indicates that CABA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.78, CABA is in line with its industry, outperforming 52.31% of the companies in the same industry.
CABA has a Quick Ratio of 4.78. This indicates that CABA is financially healthy and has no problem in meeting its short term obligations.
CABA has a Quick ratio (4.78) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.78
Quick Ratio 4.78
CABA Yearly Current Assets VS Current LiabilitesCABA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for CABA have decreased strongly by -42.63% in the last year.
EPS 1Y (TTM)-42.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-30.36%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 12.14% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-3.83%
EPS Next 2Y10.95%
EPS Next 3Y9.41%
EPS Next 5Y12.14%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CABA Yearly Revenue VS EstimatesCABA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
CABA Yearly EPS VS EstimatesCABA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CABA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CABA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CABA Price Earnings VS Forward Price EarningsCABA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CABA Per share dataCABA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.95%
EPS Next 3Y9.41%

More info and screens

0

5. Dividend

5.1 Amount

CABA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CABALETTA BIO INC

NASDAQ:CABA (9/8/2025, 12:21:00 PM)

1.675

-0.02 (-1.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)11-12 2025-11-12/bmo
Inst Owners46.34%
Inst Owner Change92.35%
Ins Owners1.68%
Ins Owner Change0%
Market Cap153.21M
Analysts83.53
Price Target11.79 (603.88%)
Short Float %7.01%
Short Ratio4.29
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-8.26%
Min EPS beat(2)-10.16%
Max EPS beat(2)-6.36%
EPS beat(4)0
Avg EPS beat(4)-4.88%
Min EPS beat(4)-10.16%
Max EPS beat(4)-1.02%
EPS beat(8)1
Avg EPS beat(8)-3.71%
EPS beat(12)4
Avg EPS beat(12)0.35%
EPS beat(16)8
Avg EPS beat(16)4.72%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-26.24%
PT rev (3m)-27.27%
EPS NQ rev (1m)26.15%
EPS NQ rev (3m)29.16%
EPS NY rev (1m)1.37%
EPS NY rev (3m)-4.47%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-14.29%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.86
P/tB 0.86
EV/EBITDA N/A
EPS(TTM)-2.71
EYN/A
EPS(NY)-1.8
Fwd EYN/A
FCF(TTM)-1.16
FCFYN/A
OCF(TTM)-1.14
OCFYN/A
SpS0
BVpS1.95
TBVpS1.95
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -64.27%
ROE -80.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-44.86%
ROA(5y)-40.06%
ROE(3y)-51.8%
ROE(5y)-45.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 31.84%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.78
Quick Ratio 4.78
Altman-Z -2.04
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)100.58%
Cap/Depr(5y)128.98%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-42.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-30.36%
EPS Next Y-3.83%
EPS Next 2Y10.95%
EPS Next 3Y9.41%
EPS Next 5Y12.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-49.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-28.76%
EBIT Next 3Y-20.07%
EBIT Next 5YN/A
FCF growth 1Y-119.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-124.91%
OCF growth 3YN/A
OCF growth 5YN/A